Opgen: Catalyst That Boom
Opgen follow up Tweet with PR stating, "As disclosed in OpGen, Inc.’s (NASDAQ: OPGN) (“OpGen” or “the Company”) July 13, 2020 press release, we have commenced marketing and promotion, on a non-exclusive basis, of certain products offered by Menarini Silicon Biosystems (MSB) to infectious disease healthcare providers and researchers. As part of the co-promotion relationship, OpGen is marketing and promoting the CELLSEARCH system, CELLSEARCH CEC kit, and certain COVID-19 related products that are sold and distributed by MSB on a non-exclusive basis. OpGen is authorized to market and promote such products in the United States, Canada, and Mexico under a strategic co-promotion agreement entered into by OpGen and MSB. As described in our tweet on August 7, 2020, the COVID-19 related products include an IgG/IgM Rapid Test Cassette that is manufactured by Healgen and sold by MSB, which is an antibody test that provides results in as fast as 10 minutes. As further described at http://www.siliconbiosystems.com/covid-19-tests, the IgG/IgM Rapid Test Cassette has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. The test has been authorized only for the presence of IgM and IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens. Under the terms of the co-promotion agreement, OpGen is entitled to certain payments based on MSB’s net sales from customers referred by OpGen for such products, including the IgG/IgM Rapid Test Cassette. The parties expect to continue to expand the portfolio of COVID-19 products available as part of the non-exclusive co-promotion relationship."
These Covid products are going to add revenues to Opgen, but taking a closer look, FDA approval for Acuitas will make this Stock BOOM!
Antibiotic Resistance was a pandemic before Covid 19. Every year in the U.S. 2.8 million individuals are contaminated with antibiotic resistant bacteria or fungi, and an excess of 35,000 individuals kick the bucket accordingly. Now, because of Covid 19, media coverage has not covered AMR like Covid 19, but you do hear doctors talk about it from time to time. It is an awareness. Also, big pharma is right now looking to buy companies that have promising antibiotics in clinical trials and also partner with companies that are disrupting the technological diagnostic space.
What is AMR?
The CDC defines it perfectly when it states, "Antibiotic resistance happens when germs like bacteria and fungi develop the ability to defeat the drugs designed to kill them. That means the germs are not killed and continue to grow. Infections caused by antibiotic-resistant germs are difficult, and sometimes impossible, to treat. In most cases, antibiotic-resistant infections require extended hospital stays, additional follow-up doctor visits, and costly and toxic alternatives. Antibiotic resistance does not mean the body is becoming resistant to antibiotics; it is that bacteria have become resistant to the antibiotics designed to kill them."
What does Opgen Have to Win The Battle Against AMR?
When it comes to diagnostic and testing for AMR, Opgen is is sitting on a gold mine. Opgens website states, "In collaboration with Merck & Co., OpGen gained access to the Study for Monitoring Antimicrobial Resistance Trends (SMART) surveillance program, a curated library of more than 250,000 bacterial isolates from over 190 hospitals in over 50 countries. Using this access to one of the world’s largest surveillance studies of antimicrobial resistance, a universe of 20,000 known resistance genes was distilled to a comprehensive set with clinical utility and one suitable for a rapid diagnostic platform. Combined with the informatics of the Acuitas Lighthouse, resistance to a broad range of antibiotics can be now determined in hours instead of the days currently required for traditional methods." This is huge, as now doctors do not have to wait days to get back results for a AMR diagnostic.
How Does AMR Relate to Covid-19?
We know that 1/4 patients that are diagnosed with Covid 19 and are hospitalized, are also infected with AMR. I want you to read this article, written by the CEO of Opgen, which talks about co-infenctions(Covid 19 & Antibiotic Resistant bacteria). In short, doctors have to wait 3-5 days in order to get results back. Oliver Schacht states, "Fast identification of specific pathogens and antibiotic resistance markers benefits hospitals in two specific ways – First, it provides a clearer view of a patient’s health for a more precise and customized treatment. In knowing which antibiotics a patient has developed a resistance to or understanding the select pathogen strain within a patient’s system, doctors can more strategically administer customized treatment and preserve limited antibiotic resources.
The second and most important benefit is enhanced infection control by minimizing the transmission risk, or “super spread” of bacterial and fungal infections, such as pneumonia, C. Auris, and more. Super spreading is not new, in fact, a study observing the SARS I outbreak in 2003 found that 76% of SARS-CoV infections were acquired in healthcare facilities, and hospitalized patients with bacterial co-infections were sources of super-spreading. In some cases, one single patient could infect more than 10 additional persons." Acuitas AMR Gene panel is the solution to
Opgen management will give update on when to expect ACUITAS FDA approval on Wednesday August 12th. This approval will make this Stock BOOM!
This company has the Diagnostics and Technology to fight Antimicrobial Resistance(AMR), The pandemic before Covid 19. Already collaborating with Merck👀. FDA is active on this front as coexisting bacteria are present in 1/5 Covid 19 Patients.
*FDA IS ACTIVE ON THE AMR FRONT. PUT OPGEN ON YOUR WATCHLIST.
FDA and AMR:
Visit this website and check out all the activities that the FDA are now pursuing regarding AMR. This topic is Booming!